AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...
Roche (RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and ...
Roche has entered an exclusive collaboration and licensing agreement with Zealand Pharma under which the parties will ...
Vietnam Investment Review on MSN2d
Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U S FDA Clearance of IND Application for ASC47 in Combination with SemaglutideASC47, an adipose-targeted muscle-preserving weight loss drug candidate for the treatment of obesity, demonstrated a half-life of up to 26 days and 40 days, respectively, in Phase Ib single ...
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...
This differs from GLP-1 agonists, which mimic incretin hormones produced in the gut to suppress appetite and regulate blood sugar. "In contrast to GLP-1s that make make people lose appetite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback